Dr. Ross Camidge, University of Colorado, explains the preference for crizotinib rather than platinum doublet chemotherapy as first line treatment for patients with ALK or ROS1 rearrangements.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
